Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population

Effect of dimethyl fumarate on lymphocytes in RRMS

(2019) Devangi Mehta et al.   NEUROLOGY

Factors associated with dimethyl fumarate-induced lymphopenia

(2019) Susana Sainz de la Maza et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis

(2019) Jan Traub et al.   BRAIN PATHOLOGY

Silent Progression in Disease Activity-Free Relapsing Multiple Sclerosis

(2019) et al.   ANNALS OF NEUROLOGY

Optimal response to dimethyl fumarate is mediated by a reduction of Th1‐like Th17 cells after 3 months of treatment

(2019) María José Mansilla et al.   CNS Neuroscience & Therapeutics

Lymphocyte counts and infection rates

(2019) Edward J. Fox et al.   Neurology-Neuroimmunology & Neuroinflammation

Risk factors for lymphopenia in patients with relapsing–remitting multiple sclerosis treated with dimethyl fumarate

(2019) Fabian Sierra Morales et al.   JOURNAL OF NEUROLOGY

Dimethyl Fumarate Reduces Microglia Functional Response to Tissue Damage and Favors Brain Iron Homeostasis

(2019) Francesca Pagani et al.   NEUROSCIENCE

Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients

(2018) Bibiana Quirant-Sánchez et al.   CNS Neuroscience & Therapeutics

Diffuse dermatophytosis occurring on dimethyl fumarate therapy

(2018) Jeffrey I Greenstein   Multiple Sclerosis Journal

Diffuse dermatophytosis occurring on dimethyl fumarate therapy

(2018) Jeffrey I Greenstein   Multiple Sclerosis Journal

Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

(2018) Yara Dadalti Fragoso et al.   Multiple Sclerosis and Related Disorders

Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count

(2018) M. Baharnoori et al.   Multiple Sclerosis and Related Disorders

Absence of Tumor Necrosis Factor Supports Alternative Activation of Macrophages in the Liver after Infection with Leishmania major

(2018) Shanshan Hu et al.   Frontiers in Immunology

Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient

(2018) Paola Perini et al.   Multiple Sclerosis and Related Disorders

Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies

(2018) Gwendoline Montes Diaz et al.   AUTOIMMUNITY REVIEWS

Functional antagonism of sphingosine-1-phosphate receptor 1 prevents cuprizone-induced demyelination

(2017) SunJa Kim et al.   GLIA

Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients

(2017) D Paolicelli et al.   JOURNAL OF NEUROIMMUNOLOGY

Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort

(2017) Alessia Manni et al.   Brain and Behavior

Disease-modifying therapies and infectious risks in multiple sclerosis

(2016) Alexander Winkelmann et al.   Nature Reviews Neurology

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia

(2014) C. Warnke et al.   NEUROLOGY

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fingolimod modulates microglial activation to augment markers of remyelination

(2011) Samuel J Jackson et al.   Journal of Neuroinflammation

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE